JAMA Network
About the Study: In this retrospective cohort study of 16,924 men with prostate cancer starting concurrent androgen deprivation therapy and an androgen receptor pathway inhibitor, metabolic syndrome and related abnormalities were frequently documented during the first year of treatment. Hypertension was the most common metabolic outcome.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
